NetworkNewsBreaks

FridayMar 03, 2017 3:45 pm

NetworkNewsBreaks – Revance Therapeutics, Inc.’s (NASDAQ: RVNC) ‘Buy’ Rating Reiterated at Aegis Capital

Aegis Capital has reiterated its ‘Buy’ rating and price target of $28 on shares of Revance Therapeutics (NASDAQ: RVNC) following release of the company's fourth quarter and full year results. Revance Therapeutics reported that it had cash and investments of $185.5 million as of December 31, 2016.  The company also said the fourth quarter was highly productive for its lead drug candidate, RT002, with the release of data from its phase 2 study for RT002 and the start of patient enrollment for two additional clinical programs evaluating the drug. Additionally, the company will be presenting clinical data from the BELMONT…

Continue Reading

FridayMar 03, 2017 3:43 pm

NetworkNewsBreaks – ViewRay, Inc. (NASDAQ: VRAY) Receives FDA Clearance for MRIdian Linac System; ‘Buy’ Rating Reiterated at Aegis Capital

Aegis Capital has reiterated its 'Buy' rating and $11 price target on shares of ViewRay, Inc. (NASDAQ: VRAY). In its recent fourth quarter and full year 2016 financial report, ViewRay reported record revenue of $22.2 million for the year, as well as $133.2 million in backlog. Additionally, the company said it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the MRIdian Linac system, the company's next generation linear accelerator-based MRI-guided radiation therapy system. The first two MRIdian Linac systems in the United States are expected to be installed at Henry Ford Hospital in Detroit and…

Continue Reading

FridayMar 03, 2017 12:32 pm

NetworkNewsBreaks – Singlepoint, Inc. (SING) CEO Discusses M&A Strategy in Interview on MoneyTV

Full-service mobile technology and marketing provider Singlepoint, Inc. (OTC: SING) is as a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” To view the show, visit www.MoneyTV.net. In this week’s episode, Singlepoint CEO Greg Lambrecht discusses the company’s recent activity, particularly as it relates to its expanded M&A strategy. “We’re really looking for companies in the cannabis business that do not touch the plant, for example a dispensary or grower like Convectium, who we have an LOI with,” Lambrecht noted in the interview.…

Continue Reading

FridayMar 03, 2017 11:51 am

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 3, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: BIOS 18.84% – News: Posts Q4, FY 2016 results CXRX 4.86% – News: Releases comment on CMA statement of objections TRTC 3.60% – News: CEO participating on two upcoming cannabis industry panels FENX 3.01% – News: Law firm posts reminder of March 13 plaintiff deadline NMUS 2.94% – News: Advances NB1222 to human dosage formulation with Catalent APDN 1.28% – News: Releases results from survey on labeling of Aloe vera RAVE 0.92% – News:…

Continue Reading

FridayMar 03, 2017 11:21 am

NetworkNewsBreaks – NEMUS Bioscience, Inc. (NMUS), Catalent to Advance Development of NB1222 Human Dosage Formulation

NEMUS Bioscience (OTCQB: NMUS) this morning said it is moving forward with Catalent Pharma Solutions to advance development of a human-dosage suppository formulation of NB1222. NB1222 is the proprietary prodrug of tetrahydrocannabinol (THC) being developed for the treatment and management of chemotherapy-induced nausea and vomiting (CINV). NB1222, also known as the prodrug THC-valine-hemisuccinate, is synthetically manufactured and is not plant-derived. "The global CINV market is a multi-billion dollar opportunity with projected growth as populations live longer, increasing the likelihood of developing a malignancy over time," Nemus CEO and chief medical officer Brian Murphy, M.D. stated in the news release. To…

Continue Reading

FridayMar 03, 2017 11:18 am

NetworkNewsBreaks – Achaogen, Inc. (NASDAQ: AKAO) Provides Updates on Drug Candidates During R&D Day

Achaogen (NASDAQ: AKAO) recently held a research and development (R&D) day to provide an overview of its programs. The meeting included presentations from members of Achaogen’s leadership team and medical community key opinion leaders. During the day, the company discussed C-Scape, its new orally administered antibacterial candidate to treat patients with complicated urinary tract infections. Achaogen plans to begin a clinical trial of C-Scape in 2017. Additionally, the R&D day provided an overview of the plazomicin program, including a review of the positive phase 3 results, progress toward the planned New Drug Application (NDA) submission and preparation for commercialization. The…

Continue Reading

FridayMar 03, 2017 11:15 am

NetworkNewsBreaks – aTyr Pharma, Inc. (NASDAQ: LIFE) Receives EMA Orphan Drug Designation for Resolaris™; Shares Pull from Early Gains

Reversing from a pre-market spike, shares of aTyr Pharma (NASDAQ: LIFE) are down 4% on word that the company’s Resolaris™ has received Orphan Drug Designation from the European Medicines Agency (EMA) for the treatment of limb girdle muscular dystrophy (LGMD) patients. Orphan designation was advised following a positive opinion by the EMA's Committee for Orphan Medicinal Products. Medicines that receive the designation are eligible for various incentives, including assistance with development of the medicine; reduced fees for marketing-authorization applications; and extended market exclusivity once the medicine is authorized. The company also received Orphan Drug Designation from the U.S. FDA earlier…

Continue Reading

ThursdayMar 02, 2017 1:22 pm

NetworkNewsBreaks – ORHub, Inc. (ORHB) Collaborates with Microsoft (NASDAQ: MSFT) on Solution to Alleviate Costly Aspect of Health Care

ORHub (OTC: ORHB) today introduced a new solution, built on Microsoft’s (NASDAQ: MSFT) Azure enterprise-grade cloud computing platform, that focuses on the single biggest cost center for health care: surgery. The company has created a value-based solution that tracks the cost of treating a condition from diagnosis to discharge, as well as outcomes that resulted from that treatment. This results in decreases in cost and improvement in outcomes by eliminating inefficiencies, duplication of effort, and errors and omissions. The company worked with Microsoft for Startups on a variety of technical engagements that helped create the digital platform's initial architecture. The…

Continue Reading

ThursdayMar 02, 2017 12:35 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 2, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: ALQA 27.11% – News: Presenting at Cowen and Company 37th Annual Health Care Conference on March 8 VBIO 19.65% – News: Develops proprietary THC pharmaceutical with reduced psychoactivity RNVA 16.36% – News: Big South Fork Medical Center receives nearly 200 job applications through online portal BKIT 13.85% – News: Presents clinical trial team INFI 12.33% – News: Presenting IPI-549 data at AACR Annual Meeting DYAI 12.00% – News: Reaches settlement with the last law…

Continue Reading

ThursdayMar 02, 2017 12:32 pm

NetworkNewsBreaks – Bridgeline Digital, Inc. (NASDAQ: BLIN) Secures Three-Year Deal with Top Regional Medical Group for iAPPS Platform

Bridgeline Digital (NASDAQ: BLIN) this morning announced that a top regional multi-specialty medical group has chosen Bridgeline’s iAPPS Platform to power its online portal and marketing automation. The medical group has agreed to a three-year SaaS subscription to iAPPS Experience Manager Pro, Bridgeline’s comprehensive experience management suite. The platform includes web content management and digital marketing automation, as well as associated professional services. Additionally, the company will develop a custom online portal for the medical group’s multiple locations. “Experience Manager Pro provides the optimal blend of features to manage website content which engages existing patients while in parallel driving new…

Continue Reading